AIO KRK-0114 / FIRE-4 Avelumab: Randomised study of the efficacy of cetuximab rechallenge in patients with RAS wild-type mCRC responding to an induction treatment in first-line with FOLFIRI plus cetuximab followed by a maintenance concept with either avelumab or 5-FU plus bevacizumab or continuation of FOLFIRI plus cetuximab

Trial Profile

AIO KRK-0114 / FIRE-4 Avelumab: Randomised study of the efficacy of cetuximab rechallenge in patients with RAS wild-type mCRC responding to an induction treatment in first-line with FOLFIRI plus cetuximab followed by a maintenance concept with either avelumab or 5-FU plus bevacizumab or continuation of FOLFIRI plus cetuximab

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Cetuximab (Primary) ; Avelumab; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms AIO KRK-0114/FIRE-4 Avelumab
  • Most Recent Events

    • 01 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top